Belpointe Asset Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Belpointe Asset Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Buy	10,229 +2,175	+27%	+$225K	0.04%	458
2026 Q1	$837K	Sell	8,054 -39	-0.5%	-$4.16K	0.03%	522
2025 Q4	$835K	Sell	8,093 -20	-0.2%	-$1.95K	0.03%	498
2025 Q3	$733K	Buy	8,113 +2,409	+42%	+$211K	0.03%	504
2025 Q2	$502K	Sell	5,704 -93	-2%	-$8.06K	0.02%	574
2025 Q1	$528K	Buy	+5,797	New	+$522K	0.03%	550
2023 Q2	–	Sell	-120	Closed	-$9.32K	–	2614
2023 Q1	$9.32K	Sell	120 -167	-58%	-$12.9K	﹤0.01%	2755
2022 Q4	$22.3K	Buy	+287	New	+$21.2K	﹤0.01%	2106

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Belpointe Asset Management's PPH Position: Q2 2026 in Review

Belpointe Asset Management increased its VanEck Pharmaceutical ETF (PPH) stake by 27% in Q2 2026, buying an estimated $225K and bringing the position to 10,229 shares worth $1.12M. The position accounts for 0.04% of the portfolio, ranked #458.

Belpointe Asset Management first reported a position in PPH in Q4 2022 and has held it in 8 quarters since. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Belpointe Asset Management held 10,229 shares of VanEck Pharmaceutical ETF worth $1.12M as of Q2 2026.
Belpointe Asset Management bought 2,175 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $225K.
VanEck Pharmaceutical ETF made up 0.04% of Belpointe Asset Management's portfolio in Q2 2026, its #458 holding.
Belpointe Asset Management first reported a position in VanEck Pharmaceutical ETF in Q4 2022 and has held it in 8 quarters since.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.